CoChat
Sign Up
Cited by 65Hepatitis Viruses Studies and EpidemiologyHepatitis B Virus StudiesViral gastroenteritis research and epidemiology

Model based estimates of long-term persistence of inactivated hepatitis A vaccine-induced antibodies in adults.

Hens, Niel, Habteab Ghebretinsae, Aklilu, Hardt, Karin, Van Damme, Pierre, Van Herck, Koen·2014·Vaccine
DOI 10.1016/j.vaccine.2013.10.088
Open this paper in CoChat — free account

Abstract

Background In this paper, we review the results of existing statistical models of the long-term persistence of hepatitis A vaccine-induced antibodies in light of recently available immunogenicity data from 2 clinical trials (up to 17 years of follow-up).Methods Healthy adult volunteers monitored annually for 17 years after the administration of the first vaccine dose in 2 double-blind, randomized clinical trials were included in this analysis. Vaccination in these studies was administered according to a 2-dose vaccination schedule: 0, 12 months in study A and 0, 6 months in study B (NCT00289757/NCT00291876). Antibodies were measured using an in-house ELISA during the first 11 years of follow-up; a commercially available ELISA was then used up to Year 17 of follow-up. Long-term antibody persistence from studies A and B was estimated using statistical models for longitudinal data. Data from studies A and B were modeled separately.Results A total of 173 participants in study A and 108 participants in study B were included in the analysis. A linear mixed model with 2 changepoints allowed all available results to be accounted for. Predictions based on this model indicated that 98% (95%CI: 94-100%) of participants in study A and 97% (95%CI: 94-100%) of participants in study B will remain seropositive 25 years after receiving the first vaccine dose. Other models using part of the data provided consistent results: ≥95% of the participants was projected to remain seropositive for ≥25 years.Conclusion This analysis, using previously used and newly selected model structures, was consistent with former estimates of seropositivity rates ≥95% for at least 25 years.

Integrity signals

Registry

Crossref · 10.1016/j.vaccine.2013.10.088

Cites

24 of 24 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Kinetic models of antibody decrease among adults indicate that protective levels persist for >40 years.

    “Kinetic models of antibody decrease among adults indicate that protective levels persist for >40 years (1302–1304).”

    From Sexually Transmitted Infections Treatment Guidelines, 2021 (2021) · cites this paper as [1304]

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Related

Authors
Hens, N., Habteab Ghebretinsae, A., Hardt, K., Van Damme, P., & Van Herck, K.
Affiliations
  • University of Antwerp (BE)
  • GlaxoSmithKline (Belgium) (BE)
ORCID
Hens, Niel
Venue
Vaccine
Publisher
Elsevier BV
Published
2014-03
Volume
32
Issue
13
Pages
1507-1513
ISSN
0264-410X (ISSN-L)
DOI
10.1016/j.vaccine.2013.10.088
OpenAlex
W2093800471
Cited by
65
References
24
Citations by year
2025: 5 · 2023: 6 · 2022: 2 · 2021: 5 · 2020: 11 · 2019: 6 · 2018: 5 · 2017: 10 · 2016: 4 · 2015: 9 · 2014: 2
FWCI
4.65
Type
journal article
Language
en
Open access
closed
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations
  • Vaccine (publishedVersion)
  • PubMed (publishedVersion)
  • Ghent University Academic Bibliography (Ghent University) (submittedVersion)
  • Document Server@UHasselt (UHasselt) (submittedVersion)
Topics
  • Health Sciences › Medicine › Hepatology › Hepatitis Viruses Studies and Epidemiology
  • Health Sciences › Medicine › Epidemiology › Hepatitis B Virus Studies
  • Health Sciences › Medicine › Infectious Diseases › Viral gastroenteritis research and epidemiology
Keywords
inactivated hepatitis A vaccine, antibody persistence, vaccine immunogenicity, linear mixed models, change-point models, two-dose vaccination schedule
MeSH terms
Adolescent, Adult, Antibody Formation, Female, Follow-Up Studies, Hepatitis A, Humans, Immunization, Secondary, Longitudinal Studies, Male, Vaccines, Inactivated, Linear Models, Hepatitis A Vaccines, Hepatitis A Antibodies, Young Adult

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review